SCHEMBL5214224

SCHEMBL5214224

OC(c1cccs1)c1cccnc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
MAPT P10636 3/20 0.46
HSD17B10 Q99714 1/20 0.46
TOP2A P11388 2/20 0.43
TOP2B Q02880 2/20 0.43
EGFR P00533 1/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
ALOX12 P18054 4/20 0.39
AHR P35869 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8198783 0.81 TOP2A (0.54) TSHRMAPTHSD17B10TOP2ATOP2B
SCHEMBL6375190 0.78 TSHR (0.48) TSHRMAPTHSD17B10TOP2ATOP2B
SCHEMBL3887083 0.73 SMN1; SMN2 (0.47) MAPTL3MBTL1ALDH1A1NAPRTKDM4E
SCHEMBL1384962 0.72 TSHR (0.57) TSHRMAPTHSD17B10TOP2ATOP2B
SCHEMBL5218484 0.71 CYP11B1 (0.40) ATMNAPRT
SCHEMBL6154951 0.70 TOP2A (0.54) TSHRMAPTHSD17B10TOP2ATOP2B
SCHEMBL2901635 0.70 CYP2C19 (0.45) MAPTHSD17B10L3MBTL1NPSR1ALDH1A1
SCHEMBL31265486 0.70 AHR (0.50) TSHRMAPTHSD17B10L3MBTL1NPSR1
SCHEMBL7219806 0.70 MAPT (0.58) TSHRMAPTHSD17B10TOP2ATOP2B
SCHEMBL23490092 0.70 NAPRT (0.42) TSHRL3MBTL1HPGDNAPRTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof ASTRAZENECA AB (SE) 2007-11-29 US disclosed
EP-1751119-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF AstraZeneca AB (SE) 2007-02-14 EP disclosed
WO-2005111001-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF ASTRAZENECA AB (SE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof VIP, CCKBR, HRH2 TSHR 3353/4885MAPT 4771/4885HSD17B10 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.